Alto Neuroscience, Inc. (ANRO)
(Delayed Data from NYSE)
$11.41 USD
+0.75 (7.04%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $11.39 -0.02 (-0.18%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Income Statements
Fiscal Year end for Alto Neuroscience, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | NA | NA |
Cost Of Goods | 0 | 0 | 0 | NA | NA |
Gross Profit | 0 | 0 | 0 | NA | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 38 | 29 | 12 | 0 | 0 |
Income After Depreciation & Amortization | -38 | -29 | -12 | 0 | 0 |
Non-Operating Income | 3 | 1 | 3 | NA | NA |
Interest Expense | 1 | 0 | 0 | NA | NA |
Pretax Income | -36 | -28 | -9 | NA | NA |
Income Taxes | 0 | 0 | 0 | NA | NA |
Minority Interest | 0 | 0 | 0 | NA | NA |
Investment Gains/Losses | 0 | 0 | 0 | NA | NA |
Other Income/Charges | 0 | 0 | 0 | NA | NA |
Income From Cont. Operations | -36 | -28 | -9 | NA | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | NA | NA |
Net Income (GAAP) | -36 | -28 | -9 | NA | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -37 | -29 | -12 | 0 | 0 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | NA | NA |
Income After Depreciation & Amortization | -38 | -29 | -12 | 0 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 3.73 | 3.45 | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -9.73 | -8.04 | NA | NA | NA |
Diluted Net EPS (GAAP) | -9.73 | -8.04 | NA | NA | NA |
Fiscal Year end for Alto Neuroscience, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | NA | NA | 0.00 |
Cost Of Goods | 0.00 | 0.00 | NA | NA | 0.00 |
Gross Profit | 0.00 | 0.00 | NA | NA | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 18.34 | 14.38 | 0.00 | 0.00 | 9.12 |
Income After SG&A, R&D, and Dept/Amort Expenses | -18.34 | -14.38 | 0.00 | 0.00 | -9.12 |
Non-Operating Income | 2.66 | 1.32 | NA | NA | 0.79 |
Interest Expense | 0.35 | 0.35 | NA | NA | 0.33 |
Pretax Income | -16.03 | -13.42 | NA | NA | -8.66 |
Income Taxes | 0.00 | 0.00 | NA | NA | 0.00 |
Minority Interest | 0.00 | 0.00 | NA | NA | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | NA | NA | 0.00 |
Other Income/Charges | 0.00 | 0.00 | NA | NA | 0.00 |
Income From Cont. Operations | -16.03 | -13.42 | NA | NA | -8.66 |
Extras & Discontinued Operations | 0.00 | 0.00 | NA | NA | 0.00 |
Net Income (GAAP) | -16.03 | -13.42 | NA | NA | -8.66 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 26.91 | 17.60 | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.60 | -0.76 | NA | NA | NA |
Diluted Net EPS (GAAP) | -0.60 | -0.76 | NA | NA | NA |